Daycare Application Template

Wednesday, November 3rd 2021. | Sample Templates

free daycare employment application template, daycare application template word, daycare job application template, daycare application template, template for daycare application, free daycare application template, daycare application template, daycare employment application template, dog daycare application form template,
daycare receipt templates
21 Daycare Receipt Templates Free PDF, Word, Excel Formats from Daycare Application Template, source:Creative Template
childcare website template galleryml
Child Care Website Templates Daycare Website Templates … from Daycare Application Template, source:Websites for Daycares
daycare
Daycare Sign-In Sheet » The Spreadsheet Page from Daycare Application Template, source:The Spreadsheet Page
formsml
Our Forms for a Safe Day Care Family Owned Newborn Day Care in … from Daycare Application Template, source:Aunties Place Family Daycare
daycare sign in form
daycare sign in form Archives – Open Office Templates from Daycare Application Template, source:Open Office Templates
formsml
Our Forms for a Safe Day Care Family Owned Newborn Day Care in … from Daycare Application Template, source:Aunties Place Family Daycare
daycare
Daycare invoice template – Wave Invoicing from Daycare Application Template, source:Wave Accounting
daycare receipt templates
10 FREE Daycare Receipt Templates (Word PDF) from Daycare Application Template, source:Word Templates Online

Nanomix Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19 Nanomix Submits Emergency Use Authorization Application for its Rapid Point-of-Care Antigen Panel to Detect COVID-19 Press release content from Business Wire. The AP news staff was not involved in its creation. https://apnews.com/press-release/business-wire/coronavirus-pandemic-business-health-a14b4c0359144e85a332c2174eba435d Press release content from Business Wire. The AP news staff was not involved in its creation. https://apnews.com/press-release/business-wire/coronavirus-pandemic-business-health-a14b4c0359144e85a332c2174eba435d Click to copy

EMERYVILLE, Calif.–(BUSINESS WIRE)–Dec 1, 2021–

Nanomix Corporation (OTCBB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced the Company has resubmitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test. The application includes additional analytical and clinical development documentation in response to FDA review comments.

The COVID-19 Antigen test cartridge is used with the Nanomix eLab Analyzer to provide electronically available results in 15 minutes.

“We look forward to the FDA’s review of our application and are proud of the work our team has done to develop a rapid, portable COVID-19 antigen test during this critical time,” stated David Ludvigson, President and Chief Executive Officer of Nanomix. “If authorized by the FDA, we believe our mobile point-of-care system will greatly increase accessibility to COVID-19 testing.”

About the Nanōmix eLab® COVID-19 Rapid Antigen Test cartridge

The Nanomix COVID-19 Rapid Antigen Test provides qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal (anterior nares) swabs. Nasal swab samples are collected using a provided swab and sample collection tube and then transferred to the single-use, microfluidic cartridge. The cartridge is run on the Nanomix eLab Analyzer which displays results in 15 minutes with the ability to print or send results electronically via Bluetooth. Additionally, the eLab system can publish Nanomix eLab COVID-19 Rapid Antigen Test results output as a QR code for privacy.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures under Contract No. 75A50120C00060.

About Nanomix Corporation

Nanomix is developing mobile point-of-care diagnostics with its Nanomix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assays address the need for faster diagnosis of critical infections as well as the rapid identification of current and prior SARS-CoV-2 infection. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit www.nano.com.

Nanomix eLab is a registered trademark.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211201005873/en/

CONTACT: LHA Investor Relations

Tirth Patel

212-201-6614

tpatel@lhai.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: INFECTIOUS DISEASES FDA FITNESS & NUTRITION CLINICAL TRIALS BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL GENERAL HEALTH

SOURCE: Nanomix Corporation

Copyright Business Wire 2021.

PUB: 12/01/2021 04:05 PM/DISC: 12/01/2021 04:06 PM

http://www.businesswire.com/news/home/20211201005873/en Click to copy

EMERYVILLE, Calif.–(BUSINESS WIRE)–Dec 1, 2021–

Nanomix Corporation (OTCBB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced the Company has resubmitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test. The application includes additional analytical and clinical development documentation in response to FDA review comments.

The COVID-19 Antigen test cartridge is used with the Nanomix eLab Analyzer to provide electronically available results in 15 minutes.

“We look forward to the FDA’s review of our application and are proud of the work our team has done to develop a rapid, portable COVID-19 antigen test during this critical time,” stated David Ludvigson, President and Chief Executive Officer of Nanomix. “If authorized by the FDA, we believe our mobile point-of-care system will greatly increase accessibility to COVID-19 testing.”

About the Nanōmix eLab® COVID-19 Rapid Antigen Test cartridge

The Nanomix COVID-19 Rapid Antigen Test provides qualitative detection of nucleocapsid antigen from SARS-CoV-2 in nasal (anterior nares) swabs. Nasal swab samples are collected using a provided swab and sample collection tube and then transferred to the single-use, microfluidic cartridge. The cartridge is run on the Nanomix eLab Analyzer which displays results in 15 minutes with the ability to print or send results electronically via Bluetooth. Additionally, the eLab system can publish Nanomix eLab COVID-19 Rapid Antigen Test results output as a QR code for privacy.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures under Contract No. 75A50120C00060.

About Nanomix Corporation

Nanomix is developing mobile point-of-care diagnostics with its Nanomix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assays address the need for faster diagnosis of critical infections as well as the rapid identification of current and prior SARS-CoV-2 infection. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes. For more information, visit www.nano.com.

Nanomix eLab is a registered trademark.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com:https://www.businesswire.com/news/home/20211201005873/en/

CONTACT: LHA Investor Relations

Tirth Patel

212-201-6614

tpatel@lhai.com

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: INFECTIOUS DISEASES FDA FITNESS & NUTRITION CLINICAL TRIALS BIOTECHNOLOGY OTHER HEALTH HEALTH PHARMACEUTICAL GENERAL HEALTH

SOURCE: Nanomix Corporation

Copyright Business Wire 2021.

PUB: 12/01/2021 04:05 PM/DISC: 12/01/2021 04:06 PM

http://www.businesswire.com/news/home/20211201005873/en

tags: , , , ,